139 related articles for article (PubMed ID: 29348487)
1. H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma.
Zhang W; Duan R; Zhang J; Cheung WKC; Gao X; Zhang R; Zhang Q; Wei M; Wang G; Zhang Q; Mei PJ; Chen HL; Kung H; Lin MC; Shen Z; Zheng J; Zhang L; Yao H
Br J Cancer; 2018 Feb; 118(4):522-533. PubMed ID: 29348487
[TBL] [Abstract][Full Text] [Related]
2. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma.
Gao X; Jiang P; Zhang Q; Liu Q; Jiang S; Liu L; Guo M; Cheng Q; Zheng J; Yao H
J Exp Clin Cancer Res; 2019 Aug; 38(1):362. PubMed ID: 31426831
[TBL] [Abstract][Full Text] [Related]
3. G-quadruplex ligand RHPS4 radiosensitizes glioblastoma xenograft in vivo through a differential targeting of bulky differentiated- and stem-cancer cells.
Berardinelli F; Tanori M; Muoio D; Buccarelli M; di Masi A; Leone S; Ricci-Vitiani L; Pallini R; Mancuso M; Antoccia A
J Exp Clin Cancer Res; 2019 Jul; 38(1):311. PubMed ID: 31311580
[TBL] [Abstract][Full Text] [Related]
4. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma.
Shen Z; Yang ZF; Gao Y; Li JC; Chen HX; Liu CC; Poon RT; Fan ST; Luk JM; Sze KH; Li TP; Gan RB; He ML; Kung HF; Lin MC
Cancer Res; 2008 Jan; 68(2):404-14. PubMed ID: 18199534
[TBL] [Abstract][Full Text] [Related]
5. Mangiferin induces radiosensitization in glioblastoma cells by inhibiting nonhomologous end joining.
Mu F; Liu T; Zheng H; Xie X; Lei T; He X; Du S; Tong R; Wang Y
Oncol Rep; 2018 Dec; 40(6):3663-3673. PubMed ID: 30272350
[TBL] [Abstract][Full Text] [Related]
6. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J
FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097
[TBL] [Abstract][Full Text] [Related]
7. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
9. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
Lal B; Xia S; Abounader R; Laterra J
Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.
Zhang Y; Farenholtz KE; Yang Y; Guessous F; Dipierro CG; Calvert VS; Deng J; Schiff D; Xin W; Lee JK; Purow B; Christensen J; Petricoin E; Abounader R
Clin Cancer Res; 2013 Mar; 19(6):1433-44. PubMed ID: 23386689
[TBL] [Abstract][Full Text] [Related]
11. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
12. miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
Lan F; Yu H; Hu M; Xia T; Yue X
J Neurochem; 2015 Oct; 135(2):274-86. PubMed ID: 26250785
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
[TBL] [Abstract][Full Text] [Related]
14. Validation of Enhancing Effects of Curcumin on Radiotherapy with F98/
Wang WH; Shen CY; Chien YC; Chang WS; Tsai CW; Lin YH; Hwang JJ
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575632
[TBL] [Abstract][Full Text] [Related]
15. A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma.
Shen Z; Wong OG; Yao RY; Liang J; Kung HF; Lin MC
Cancer Lett; 2008 Dec; 272(2):268-76. PubMed ID: 18722051
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP.
Shin SW; Choi C; Lee GH; Son A; Kim SH; Park HC; Batinic-Haberle I; Park W
Antioxid Redox Signal; 2017 Nov; 27(14):1067-1082. PubMed ID: 28358581
[TBL] [Abstract][Full Text] [Related]
17. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway.
Yao Y; Fang ZP; Chen H; Yue L; Min DL; Tang LN; Yu WX; Kung HF; Lin MC; Shen Z
Cancer Gene Ther; 2012 Sep; 19(9):601-8. PubMed ID: 22767217
[TBL] [Abstract][Full Text] [Related]
18. Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.
Mikami K; Medová M; Nisa L; Francica P; Glück AA; Tschan MP; Blaukat A; Bladt F; Aebersold DM; Zimmer Y
Mol Cancer Res; 2015 Dec; 13(12):1544-53. PubMed ID: 26358474
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells.
Lee JS; Oh E; Yoo JY; Choi KS; Yoon MJ; Yun CO
Oncotarget; 2015 Feb; 6(6):4051-65. PubMed ID: 25726528
[TBL] [Abstract][Full Text] [Related]
20. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
